Latest studies
- Ongoing, recruitingTherapeutic use (Phase IV)
I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
This study looks at how safe and effective a medicine called baricitinib is for people with rheumatoid arthritis, compared to other common treatments. It will see how long it takes for a blood clot to happen. This is a long-term study that will last over five years.
Rheumatoid ArthritisLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionLithuania - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.
This study looks at how a medicine called radium-223 moves through the bodies of men with prostate cancer who are receiving this treatment. It helps doctors understand how the drug works and is processed by the body.
Prostate cancerLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
This study looks at a new medicine called dexpramipexole for severe asthma. It wants to see if the medicine can reduce asthma flare-ups and improve breathing over 52 weeks. Researchers will compare it to a dummy medicine to see if it works and is safe.
Severe eosinophilic asthmaLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Lithuania - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
This study is looking at a new medicine, GME751, which is very similar to an existing cancer drug called Keytruda (pembrolizumab). It's for people with certain stages of skin cancer (melanoma) who need treatment after their initial cancer care. We want to see how GME751 works in the body compared to Keytruda.
MelanomaLithuania - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Participants with Advanced Prostate Cancer
This study looks at a new drug, Teverelix, for men with advanced prostate cancer. We want to see how well it lowers testosterone, a hormone that can make prostate cancer grow, and if it's safe to use.
Advanced prostate cancerLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
This study is comparing a new version of a rheumatoid arthritis medicine, called DRL_AB, with an existing one, Orencia. It aims to see if the new medicine works as well, is safe, and causes a similar immune response in people with moderate to severe rheumatoid arthritis.
Rheumatoid ArthritisLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Lithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Thromboembolic diseaseLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaLithuania - Ongoing, recruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
Hidradenitis Suppurativa (HS)Lithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Lithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin.
This study looks at a medicine called gliclazide MR to see if it helps people with type 2 diabetes whose blood sugar isn't well controlled, even when using other common diabetes medicines like dapagliflozin or metformin. It aims to see if it's safe and effective.
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metforminLithuania - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
This study is testing a new medicine, NECVAX-NEO1, alongside standard cancer treatments (like anti-PD-1 or anti-PD-L1 drugs). It's for people with certain solid tumours like lung cancer or melanoma. This early-stage trial aims to see if the new medicine is safe and how it works in the body.
Non-Small Cell Lung Cancercutaneous melanomaurothelial cancerrenal cell cancerLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.
Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)Lithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
MigraineLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
This study is testing a new medicine, OMS906, for certain kidney diseases. We want to see if it's safe, how it works in the body, and if it helps improve kidney function in people with C3G and ICGN conditions.
C3 Glomerulopathy and Idiopathic Immune Complex-Mediated GlomerulonephritisLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
Chronic Obstructive Pulmonary DiseaseLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.
This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.
Chronic UrticariaLithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Lithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Lithuania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancers that haven't responded to previous chemotherapy. It compares a new drug, nemvaleukin alfa, with an existing cancer drug, pembrolizumab, against standard chemotherapy treatments to see if it helps people live longer.
Platinum-Resistant Epithelial OvarianFallopian Tubeor Primary Peritoneal CancerLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine, VTX002, for people with moderate to severe ulcerative colitis. Researchers want to see if it helps reduce symptoms and improve the condition, compared to a dummy pill.
Moderately to Severely Active Ulcerative ColitisLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
This study is looking at a new medicine called VE202 for people with mild to moderate ulcerative colitis. It aims to see if VE202 can help improve the condition and if it's safe to use compared to a dummy medicine.
Mild-to-moderate ulcerative colitisLithuania - AuthorisedTherapeutic exploratory (Phase II)
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
This study is looking at new ways to treat advanced ovarian cancer that has come back. It tests combinations of new drugs, olaparib, durvalumab, and a vaccine called UV1, to see if they can stop the cancer from growing for longer in patients whose cancer does not have a specific BRCA gene change.
Ovarian cancerLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
Chronic Inducible UrticariaLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies (The FIOL-study)
This study looks at a medicine called osimertinib (also known as Tagrisso) for a type of lung cancer with a specific gene change (EGFR mutation). We want to see how well it shrinks tumours and helps people live longer, while also checking if it's safe.
EGFR-mutated non-small cell lung cancerLithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
This study, called Ixion 2.0, is investigating a new treatment called FX06 for a severe lung condition called Acute Respiratory Distress Syndrome (ARDS). It aims to see if FX06 helps patients breathe on their own sooner compared to a dummy treatment.
Acute Respiratory Distress Syndrome (ARDS)Lithuania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.
Acute Bacterial Skin and Skin Structure InfectionsLithuania - Active not recruitingPHASE3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.
Atherosclerotic Cardiovascular DiseaseLithuania - Active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
Small Cell Lung CancerLithuania - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseLithuania - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisLithuania - Active not recruitingPHASE3
ABTECT - Maintenance
This study looks at a new drug, ABX464, for people with ulcerative colitis. It's for those who haven't responded well to other treatments. The study checks if ABX464 can help keep symptoms under control over a long time and if it is safe to use.
Ulcerative ColitisLithuania - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisLithuania - Active not recruitingPHASE3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
This study is testing a new medicine called Mim8 for people with haemophilia A, including those with inhibitors. Mim8 aims to prevent bleeding episodes by helping blood clot. It's for people already in other Mim8 studies.
Haemophilia AHaemophilia A With InhibitorsLithuania - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisLithuania - Active not recruitingPHASE3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.
Moderate-to-Severe Atopic DermatitisLithuania - Recruiting
Fluid Administration and Fluid Accumulation in the Intensive Care Unit
This study looks at how fluids are given to very sick adults in intensive care and if too much fluid builds up. Researchers want to understand why this happens and how it affects patients' recovery, all while collecting information from hospitals worldwide.
Fluid AccumulationFluid TherapyFluid OverloadLithuania - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaLithuania - Active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
Lupus NephritisLithuania - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientLithuania - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisLithuania